Nasus Pharma(NSRX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Nasus Pharma
NSRX.US
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
4.933 T
NSRX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ProRx Pharma Redefines Hormone Therapy with Needle-Free Oral Testosterone Option

    ProRx Pharma has launched a needle-free oral testosterone formulation, aimed at enhancing hormone therapy accessibility. This innovative product allows healthcare providers to offer testosterone replacement therapy (TRT) without the complexities of injectables, making it suitable for telemedicine and clinics. The oral option reduces patient risks associated with injections and improves hormone level consistency. Produced in a state-licensed facility, ProRx's oral testosterone is designed to meet U.S. Pharmacopeia standards, ensuring safety and reliability for patients.

    biopharmadive·
    US
    RXDX
    0.00%
    DE
    GME
    0.00%
    US
    NSRX
    -11.83%
    biopharmadive·
    US
    RXDX
    0.00%
    DE
    GME
    0.00%
    US
    NSRX
    -11.83%

    Nasus Pharma Reports Positive Interim Phase 2 Results for Intranasal Epinephrine NS002

    Nasus Pharma Ltd. reported positive interim results from its Phase 2 study of NS002, an intranasal epinephrine formulation for anaphylaxis treatment. The data indicated faster absorption and higher peak concentrations compared to the EpiPen®, with 91% of participants reaching the plasma threshold at 5 minutes. NS002 was well-tolerated with no serious adverse events. Full results are expected by Q1 2026, with a pivotal study planned for Q4 2026.

    Reuters·
    US
    NSRX
    -11.83%
    Reuters·
    US
    NSRX
    -11.83%

    U.S. stock market midday update: Nasus Pharma plummets 12.57%, trading volume surges, market volatility draws attention

    Nasus Pharma fell 12.57%; Eli Lilly fell 0.17%, with a transaction volume of USD 1.49 billion; Johnson & Johnson fell 0.31%, with a transaction volume of USD 781 million; Pfizer rose 1.10%, with a transaction volume of USD 631 million; AstraZeneca fell 0.40%, with a market value of USD 284 billion

    Tracking Unusual Activity·
    US
    NSRX
    -11.83%
    Tracking Unusual Activity·
    US
    NSRX
    -11.83%

    Nasus Pharma Publishes 2025 Shareholder Letter

    Nasus Pharma Ltd. has released a shareholder letter from CEO Dan Teleman, highlighting recent advancements. These include progress in the clinical development of NS002, new collaborations with Aptar France S.A.S. and AptarGroup Inc., and Health Canada's authorization for a Phase 2 clinical study of NS002. The first patient has been dosed, with results expected by Q1 2026. The full letter is available online.

    Reuters·
    US
    NSRX
    -11.83%
    Reuters·
    US
    NSRX
    -11.83%

    Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development

    Nasus Pharma Ltd. has expanded its collaboration with Aptar France S.A.S. and AptarGroup Inc. to advance the clinical development and commercialization of NS002, an intranasal epinephrine powder. The partnership grants Nasus access to Aptar's Unit Dose System technology, aiming to expedite NS002's market entry by utilizing established regulatory and supply chain capabilities.

    Reuters·
    US
    NSRX
    -11.83%
    Reuters·
    US
    NSRX
    -11.83%
    © 2026 Longbridge｜Disclaimer